{"product_id":"calliditas-business-model-canvas","title":"Calliditas Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCalliditas Business Model Canvas: Actionable Blueprint for Investors \u0026amp; Founders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Calliditas’s business model — a concise, actionable Business Model Canvas that maps value propositions, revenue streams, key partners, and growth levers; perfect for investors, consultants, and founders who need a ready-to-use, editable strategy tool to benchmark, plan, and scale with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAsahi Kasei Parent Group Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy end-2025, integration with parent Asahi Kasei delivers Calliditas ~¥40bn (≈$280m) in committed capital and access to a global supply chain across 20+ manufacturing sites, enabling 30–40% unit-cost improvements and faster launches in 15 additional markets; shared pharma manufacturing expertise and joint regulatory teams cut time-to-approval by an estimated 6–12 months versus standalone filings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Licensing Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCalliditas partners with Everest Medicines for Nefecon commercialization in Greater China and South Korea; Everest holds regional licenses and led the 2024 regulatory submissions that target \u0026gt;800M patients across those markets. These license deals let Calliditas book tiered royalties (typically mid-teens) and milestone payments—avoiding a direct Asian sales buildout that could cost an estimated $50–120M to establish.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEuropean Distribution Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe company maintains a commercial distribution agreement with STADA Arzneimittel for Kinpeygo across the European Economic Area, leveraging STADA’s sales reach of ~40,000 pharmacy and hospital customers and its 2024 EMEA revenue of €2.1bn to accelerate market access; this alliance supports roll-out across 27 EU markets and ensures Kinpeygo’s availability amid varied national reimbursement regimes for IgA nephropathy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCalliditas outsources production to contract manufacturing organizations (CMOs) for its Nefecon delayed-release capsules and pipeline TARC (targeted release) candidates, keeping capex low while meeting EU GMP and US FDA technical specs; in 2024 CMOs produced commercial batches covering ~70% of forecasted 2025 demand. \u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAsset-light model: reduces fixed manufacturing spend\u003c\/li\u003e\n\u003cli\u003eQuality: partners comply with EU GMP\/FDA standards\u003c\/li\u003e\n\u003cli\u003eScalability: capacity booked for ~30,000 patient-equivalent doses in 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Clinical Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCalliditas partners with leading renal research centers and Clinical Research Organizations to run complex late-stage trials for Alport syndrome and primary biliary cholangitis (PBC), lowering trial timelines—Phase III median completion cut by ~18% in recent nephrology studies (2018–2024).\u003c\/p\u003e\n\u003cp\u003eThese collaborations secure scientific rigor for FDA and EMA submissions, leveraging expert PIs and CRO networks that helped Calliditas budget ~€60–80M per pivotal program in 2023–2025 projections.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus: Alport syndrome, PBC\u003c\/li\u003e\n\u003cli\u003eBenefit: Faster Phase III (~18% time savings)\u003c\/li\u003e\n\u003cli\u003eBudget: ~€60–80M per pivotal program\u003c\/li\u003e\n\u003cli\u003eGoal: FDA\/EMA-grade data and expert PIs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic partnerships cut costs 30–40%, speed approvals 6–12m, unlock global market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eParent Asahi Kasei provides ~¥40bn (~$280m) committed capital and global supply chain access (20+ sites) cutting unit costs 30–40% and approval time 6–12 months; Everest Medicines covers Greater China\/South Korea with mid‑teens royalties and avoids a $50–120m Asian buildout; STADA gives access to ~40,000 customers across 27 EU markets; CMOs cover ~70% of 2025 demand; pivotal trials budget €60–80m.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024–25 impact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsahi Kasei\u003c\/td\u003e\n\u003ctd\u003e¥40bn committed\u003c\/td\u003e\n\u003ctd\u003e30–40% cost ↓; 6–12m faster\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEverest Medicines\u003c\/td\u003e\n\u003ctd\u003eRegional license\u003c\/td\u003e\n\u003ctd\u003eMid‑teens royalties; avoids $50–120m capex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSTADA\u003c\/td\u003e\n\u003ctd\u003e~40,000 customers\u003c\/td\u003e\n\u003ctd\u003e27 EU markets access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003e70% demand\u003c\/td\u003e\n\u003ctd\u003eLow capex; EU GMP\/FDA compliant\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\/centers\u003c\/td\u003e\n\u003ctd\u003e€60–80m per program\u003c\/td\u003e\n\u003ctd\u003e~18% faster Phase III\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Calliditas detailing customer segments, channels, value propositions, revenue streams, key activities, partners, resources, cost structure, and governance—aligned to the company’s clinical-stage rare-disease biotech strategy and ready for presentations or investor review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level, editable Business Model Canvas tailored to Calliditas that condenses its commercial and clinical strategy into a one-page snapshot, ideal for quick review and boardroom discussion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Pipeline Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCalliditas invests ~€45M R\u0026amp;D annually (2024 report) to expand its NOX inhibitor platform and advance setanaxib through multiple orphan indications, with four active clinical trials including a Phase 3 renal program and two Phase 2s in hepatic and fibrotic diseases, aiming to widen post-Tolvaptan revenue streams and sustain pipeline-driven growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Execution and Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA specialized US sales force directly promotes TARPEYO, educating nephrologists on targeted budesonide for IgA nephropathy to drive prescriptions; Calliditas reported 2024 US net product sales of SEK 1,020m (≈USD 94m) supporting this push. Effective commercial execution—measured by prescription growth (2024 Rx share up ~35% year\/year) and payer access covering \u0026gt;80% lives—sustains market leadership in the renal space.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCalliditas must manage complex global regulations to keep FDA and EMA approvals for Nefecon (approved 2021 in EU, 2021 supplemental in US trials ongoing) and to advance pipeline assets; regulatory filings drive timing of peak-sales and funding needs—regulatory delays can cut revenue by 20–40% in a given year. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Access and Reimbursement Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCalliditas engages payers and HTA bodies to secure favorable pricing and coverage, targeting reduced patient copays and inclusion in hospital formularies; in 2024 payer negotiations helped achieve list-price access in 18 EU countries and led to average patient OOP (out-of-pocket) reductions of ~35% in treated cohorts.\u003c\/p\u003e\n\u003cp\u003eStrategic payer engagement drives uptake for high-value orphan drugs—Calliditas reported net product sales of SEK 741m in 2024, showing reimbursement success directly lifts commercial potential.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18 EU countries with list-price access in 2024\u003c\/li\u003e\n\u003cli\u003e~35% average patient OOP reduction\u003c\/li\u003e\n\u003cli\u003eSEK 741m net product sales in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCalliditas runs end-to-end logistics for temperature-sensitive orphan drugs, coordinating CMOs, distributors, and specialty pharmacies to keep product integrity and meet regulatory cold-chain standards; in 2024 they targeted 98% on-time deliveries across 30+ markets to avoid stockouts.\u003c\/p\u003e\n\u003cp\u003eSupply chain resilience includes dual-sourcing key inputs, safety stock covering 3–4 months of demand, and monitoring lot-level cold-chain data to reduce spoilage under 0.5% annually.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e98% on-time delivery target (2024)\u003c\/li\u003e\n\u003cli\u003e30+ global markets covered\u003c\/li\u003e\n\u003cli\u003e3–4 months safety stock\u003c\/li\u003e\n\u003cli\u003e\u0026lt;0.5% annual spoilage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCalliditas: €45M R\u0026amp;D Fuels Setanaxib Trials as TARPEYO US Sales Surge to SEK1,020m\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCalliditas spends ~€45M R\u0026amp;D (2024) to advance setanaxib across 4 trials (including Phase 3 renal) and sustain pipeline growth; US TARPEYO sales SEK 1,020m (≈USD 94m) in 2024 with Rx share +35% YoY and \u0026gt;80% payer access; supply chain targets 98% on-time, \u0026lt;0.5% spoilage, 3–4 months safety stock; 18 EU list-price countries, SEK 741m net sales (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e~€45M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTARPEYO US sales\u003c\/td\u003e\n\u003ctd\u003eSEK 1,020m (~USD 94m)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet product sales\u003c\/td\u003e\n\u003ctd\u003eSEK 741m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRx share growth\u003c\/td\u003e\n\u003ctd\u003e+35% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer access\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;80% lives\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU list-price countries\u003c\/td\u003e\n\u003ctd\u003e18\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time delivery target\u003c\/td\u003e\n\u003ctd\u003e98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpoilage\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSafety stock\u003c\/td\u003e\n\u003ctd\u003e3–4 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview you see is the actual Calliditas Business Model Canvas document, not a mockup—it's a direct excerpt from the final file you’ll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you’ll get this exact document in full, formatted and ready to edit, present, or share, with no hidden sections or surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749862519161,"sku":"calliditas-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/calliditas-business-model-canvas.png?v=1772219362","url":"https:\/\/matrixbcg.com\/products\/calliditas-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}